N-Acetylcysteine and Liver Transplant. Advantages of its Administration in Multi-Organ Donors Especially During World-Economical-Crisis. Long-Term Sub-Group Analysis in a Randomized Study

Background. Liver transplantation (LT) is the main indication for the treatment of end-stage liver disease but have to face organ shortages. Using marginal donors is an option to increase the donor pool. Previous studies showed that the graft procured using N-acetylcysteine (NAC) pro vides a longer survival compared to perfusion with standard solutions, especially in marginal liver donors. We now evaluate the effect of NAC perfusion compared to control (no NAC proto col) at a 5-year follow-up, with a special focus on the overall survival (OS) and graft survival. Methods. Single-center, retrospective review of the OS and graft survival among NAC and control group, with a sub-stratification based on the LT indication. Results. 140 donors were enrolled: 69 in the NAC protocol and 71 in the control group. The 5-year OS was 84% in the NAC protocol compared to 63% in the control (P=.0045). In LT for HCC, the OS at 5 years was 80% and 55% in the study group and control group, respectively (P=.04), with no statistical difference in the RFS (P=.46). Furthermore, in cost analysis, the resources needed for the NAC protocol is negligible compared to the control group. Beneficial tendency of NAC protocol application has been seen in the other organs (lungs, hearts, pancreas, kidney and intestine) Conclusion. The application of NAC infusion in liver donors improves the overall survival of the recipient, especially in the HCC and HCV LT indications.